Trials / Completed
CompletedNCT00157950
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 9 Years – 23 Years
- Healthy volunteers
- Accepted
Summary
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Gardasil™ | Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6) |
| BIOLOGICAL | Placebo | Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6) |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2005-09-12
- Last updated
- 2016-02-04
- Results posted
- 2010-09-14
Source: ClinicalTrials.gov record NCT00157950. Inclusion in this directory is not an endorsement.